Symbols / ALLO Stock $2.05 -0.97% Allogene Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
ALLO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David D. Chang M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 707.57M
Enterprise Value 521.73M
Income -173.76M
Sales —
FCF (ttm) -69.94M
Book/sh 1.14
Cash/sh 0.77
Employees 150
Insider 10d —
IPO Oct 11, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.00
PEG —
P/S —
P/B 1.80
P/C —
EV/EBITDA -2.97
EV/Sales —
Quick Ratio 9.47
Current Ratio 9.65
Debt/Eq 29.06
LT Debt/Eq —
EPS (ttm) -0.77
EPS next Y -0.68
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-12
Earnings (prior) 2026-05-13
ROA -25.97%
ROE -52.32%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 345.15M
Shs Float 270.67M
Insider Own 11.03%
Instit Own 53.33%
Short Float 14.26%
Short Ratio 6.79
Short Interest 44.48M
52W High 4.46
vs 52W High -54.04%
52W Low 0.98
vs 52W Low 109.18%
Beta 0.46
Impl. Vol. 3.13%
Rel Volume 0.92
Avg Volume 10.35M
Volume 9.55M
Target (mean) $8.48
Tgt Median $9.00
Tgt Low $3.85
Tgt High $14.00
# Analysts 10
Recom Buy
Prev Close $2.07
Price $2.05
Change -0.97%
About

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.49
Mean price target
2. Current target
$2.05
Latest analyst target
3. DCF / Fair value
$-3.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.05
Low
$3.85
High
$14.00
Mean
$8.49

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-16 up JP Morgan Underweight → Neutral —
2026-04-16 main HC Wainwright & Co. Buy → Buy $11
2026-04-15 main Jefferies Buy → Buy $10
2026-04-14 main Bernstein Market Perform → Market Perform $4
2026-04-14 main Argus Research Market Perform → Market Perform $4
2026-04-14 main Citizens Market Outperform → Market Outperform $8
2026-04-14 main Baird Outperform → Outperform $9
2026-04-14 main HC Wainwright & Co. Buy → Buy $12
2026-03-13 main Canaccord Genuity Buy → Buy $14
2026-03-13 main Piper Sandler Overweight → Overweight $8
2026-01-09 up Citizens Market Perform → Market Outperform $5
2026-01-07 init UBS — → Buy $8
2025-10-10 down JP Morgan Neutral → Underweight —
2025-08-04 reit JMP Securities Market Perform → Market Perform —
2025-08-04 down JP Morgan Overweight → Neutral —
2025-08-01 main Oppenheimer Outperform → Outperform $7
2025-05-15 main Citigroup Buy → Buy $4
2025-05-14 main Truist Securities Buy → Buy $10
2025-05-14 main Piper Sandler Overweight → Overweight $7
2025-05-14 reit RBC Capital Outperform → Outperform $10
News
RSS: Latest ALLO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 YOSHIYAMA ANNIE Officer — 9,586 $2.31 $22,144
2026-03-31 BENESKI BENJAMIN MACHINAS Chief Technology Officer — 2,867 $2.50 $7,168
2026-03-16 CHANG DAVID D Chief Executive Officer — 47,763 $2.47 $117,975
2026-03-16 BENESKI BENJAMIN MACHINAS Chief Technology Officer — 4,835 $2.47 $11,942
2026-03-02 BENESKI BENJAMIN MACHINAS Chief Technology Officer — 7,132 $2.60 $18,543
2026-02-02 DOUGLAS EARL MARTIN General Counsel — 22,900 $1.76 $40,304
2026-02-02 CHANG DAVID D Chief Executive Officer — 95,269 $1.80 $171,484
2026-02-02 PARKER GEOFFREY M Chief Financial Officer — 24,001 $1.76 $42,242
2026-02-02 YOSHIYAMA ANNIE Officer — 4,167 $1.72 $7,167
2026-02-02 ROBERTS ZACHARY Officer — 35,700 $1.77 $63,189
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.02
-76.84%
0.10
-39.10%
0.16
Operating Revenue
0.00
-100.00%
0.02
-76.84%
0.10
-39.10%
0.16
Operating Expense
206.93
-19.64%
257.50
-18.15%
314.59
-6.29%
335.69
Research And Development
150.15
-21.92%
192.30
-20.84%
242.91
-5.25%
256.39
Selling General And Administration
56.78
-12.92%
65.20
-9.02%
71.67
-9.62%
79.31
General And Administrative Expense
56.78
-12.92%
65.20
-9.02%
71.67
-9.62%
79.31
Other Gand A
56.78
-12.92%
65.20
-9.02%
71.67
-9.62%
79.31
Total Expenses
206.93
-19.64%
257.50
-18.15%
314.59
-6.29%
335.69
Operating Income
-206.93
+19.63%
-257.48
+18.13%
-314.49
+6.27%
-335.54
Total Operating Income As Reported
-209.31
+23.38%
-273.20
+16.64%
-327.74
+2.32%
-335.54
EBITDA
-177.45
+27.07%
-243.33
+22.28%
-313.07
+2.54%
-321.24
Normalized EBITDA
-175.07
+23.08%
-227.61
+24.08%
-299.82
+6.67%
-321.24
Reconciled Depreciation
12.36
-9.38%
13.64
-3.94%
14.20
-0.67%
14.29
EBIT
-189.81
+26.13%
-256.97
+21.48%
-327.26
+2.47%
-335.54
Total Unusual Items
-2.38
+84.84%
-15.72
-18.66%
-13.24
—
Total Unusual Items Excluding Goodwill
-2.38
+84.84%
-15.72
-18.66%
-13.24
—
Special Income Charges
-2.38
+84.84%
-15.72
-18.66%
-13.24
—
Impairment Of Capital Assets
2.38
-84.84%
15.72
+18.66%
13.24
—
Net Income
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Pretax Income
-190.89
+25.77%
-257.15
+21.43%
-327.26
+3.86%
-340.41
Net Non Operating Interest Income Expense
18.21
-8.80%
19.97
+9.09%
18.31
+300.94%
4.57
Interest Expense Non Operating
1.07
+493.92%
0.18
0.00
—
Net Interest Income
18.21
-8.80%
19.97
+9.09%
18.31
+300.94%
4.57
Interest Expense
1.07
+493.92%
0.18
0.00
—
Interest Income Non Operating
19.29
-4.29%
20.15
+10.08%
18.31
+300.94%
4.57
Interest Income
19.29
-4.29%
20.15
+10.08%
18.31
+300.94%
4.57
Other Income Expense
-2.17
+88.96%
-19.64
+36.82%
-31.08
-229.10%
-9.44
Other Non Operating Income Expenses
0.21
+105.48%
-3.92
+78.02%
-17.84
-88.85%
-9.44
Tax Provision
0.00
-100.00%
0.44
0.00
—
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-3.30
0.00
0.00
Net Income Including Noncontrolling Interests
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Net Income From Continuing Operation Net Minority Interest
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Net Income From Continuing And Discontinued Operation
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Net Income Continuous Operations
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Normalized Income
-188.50
+23.11%
-245.17
+21.92%
-314.02
+7.75%
-340.41
Net Income Common Stockholders
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Diluted EPS
-0.87
+34.09%
-1.32
+36.84%
-2.09
+9.91%
-2.32
Basic EPS
-0.87
+34.09%
-1.32
+36.84%
-2.09
+9.91%
-2.32
Basic Average Shares
220.62
+13.25%
194.81
+24.14%
156.93
+9.63%
143.15
Diluted Average Shares
220.62
+13.25%
194.81
+24.14%
156.93
+9.63%
143.15
Diluted NI Availto Com Stockholders
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
415.90
-24.20%
548.71
-14.64%
642.84
-21.76%
821.58
Current Assets
257.75
-15.04%
303.39
-33.92%
459.12
-13.18%
528.82
Cash Cash Equivalents And Short Term Investments
250.21
-14.45%
292.48
-34.82%
448.70
-13.27%
517.32
Cash And Cash Equivalents
51.69
-31.28%
75.22
-9.54%
83.16
+34.33%
61.90
Cash Equivalents
—
—
78.54
—
Cash Financial
—
—
4.62
—
Other Short Term Investments
198.52
-8.62%
217.26
-40.57%
365.54
-19.73%
455.42
Prepaid Assets
—
—
—
—
Other Current Assets
7.54
-30.90%
10.91
+4.72%
10.42
-9.44%
11.50
Total Non Current Assets
158.16
-35.53%
245.32
+33.53%
183.72
-37.24%
292.75
Net PPE
112.73
-14.12%
131.26
-19.56%
163.18
-16.93%
196.43
Gross PPE
185.26
-4.41%
193.80
-9.55%
214.26
-8.17%
233.32
Accumulated Depreciation
-72.53
-15.98%
-62.54
-22.42%
-51.08
-38.50%
-36.88
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
9.09
+2.42%
8.87
+1.00%
8.78
+2.80%
8.54
Construction In Progress
—
—
0.00
-100.00%
0.03
Other Properties
68.64
-10.63%
76.80
-20.71%
96.86
-16.64%
116.19
Leases
107.54
-0.55%
108.13
-0.45%
108.62
+0.07%
108.55
Investments And Advances
8.04
-90.03%
80.67
+2113.25%
3.65
-95.23%
76.47
Long Term Equity Investment
—
0.00
-100.00%
3.65
-78.95%
17.32
Other Non Current Assets
37.39
+11.97%
33.39
+97.62%
16.90
-14.91%
19.86
Total Liabilities Net Minority Interest
123.36
-2.50%
126.53
-3.12%
130.60
-15.57%
154.70
Current Liabilities
32.51
-8.47%
35.52
-4.20%
37.08
-30.99%
53.73
Payables And Accrued Expenses
14.06
-11.36%
15.87
-9.60%
17.55
-40.89%
29.70
Payables
4.27
-20.84%
5.39
-8.53%
5.90
-57.54%
13.89
Accounts Payable
4.27
-20.84%
5.39
-8.53%
5.90
-57.54%
13.89
Current Accrued Expenses
9.79
-6.48%
10.47
-10.14%
11.66
-26.26%
15.81
Pensionand Other Post Retirement Benefit Plans Current
10.24
-15.68%
12.15
-4.10%
12.66
-29.38%
17.93
Current Debt And Capital Lease Obligation
8.21
+9.31%
7.51
+10.83%
6.78
+12.88%
6.00
Current Capital Lease Obligation
8.21
+9.31%
7.51
+10.83%
6.78
+12.88%
6.00
Current Deferred Liabilities
—
—
0.09
-9.47%
0.10
Current Deferred Revenue
—
—
0.09
-9.47%
0.10
Other Current Liabilities
—
—
0.09
—
Total Non Current Liabilities Net Minority Interest
90.85
-0.17%
91.01
-2.69%
93.53
-7.37%
100.97
Long Term Debt And Capital Lease Obligation
75.05
-9.85%
83.25
-5.77%
88.35
-7.12%
95.12
Long Term Capital Lease Obligation
75.05
-9.85%
83.25
-5.77%
88.35
-7.12%
95.12
Other Non Current Liabilities
15.80
+103.63%
7.76
+49.86%
5.18
-11.42%
5.85
Stockholders Equity
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Common Stock Equity
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Capital Stock
0.23
+8.02%
0.21
+25.44%
0.17
+17.36%
0.14
Common Stock
0.23
+8.02%
0.21
+25.44%
0.17
+17.36%
0.14
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
229.41
+8.11%
212.21
+25.83%
168.64
+16.76%
144.44
Ordinary Shares Number
229.41
+8.11%
212.21
+25.83%
168.64
+16.76%
144.44
Additional Paid In Capital
2,302.75
+2.72%
2,241.88
+8.03%
2,075.25
+8.56%
1,911.63
Retained Earnings
-2,010.71
-10.49%
-1,819.82
-16.49%
-1,562.23
-26.50%
-1,234.97
Gains Losses Not Affecting Retained Earnings
0.27
+402.25%
-0.09
+90.68%
-0.95
+90.38%
-9.93
Other Equity Adjustments
0.27
+402.25%
-0.09
+90.68%
-0.95
+90.38%
-9.93
Total Equity Gross Minority Interest
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Total Capitalization
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Working Capital
225.24
-15.91%
267.86
-36.53%
422.04
-11.17%
475.10
Invested Capital
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Total Debt
83.25
-8.27%
90.76
-4.59%
95.12
-5.94%
101.12
Capital Lease Obligations
83.25
-8.27%
90.76
-4.59%
95.12
-5.94%
101.12
Net Tangible Assets
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Tangible Book Value
292.54
-30.71%
422.18
-17.58%
512.23
-23.19%
666.88
Available For Sale Securities
8.04
-90.03%
80.67
—
59.15
Investmentin Financial Assets
8.04
-90.03%
80.67
0.00
-100.00%
59.15
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-149.25
+25.49%
-200.30
+15.75%
-237.73
-7.81%
-220.52
Cash Flow From Continuing Operating Activities
-149.25
+25.49%
-200.30
+15.75%
-237.73
-7.81%
-220.52
Net Income From Continuing Operations
-190.89
+25.90%
-257.59
+21.29%
-327.26
+3.86%
-340.41
Depreciation Amortization Depletion
12.36
-9.38%
13.64
-3.94%
14.20
-0.67%
14.29
Depreciation
—
—
—
14.29
Amortization Cash Flow
—
—
—
0.00
Depreciation And Amortization
12.36
-9.38%
13.64
-3.94%
14.20
-0.67%
14.29
Amortization Of Intangibles
—
—
—
0.00
Other Non Cash Items
4.36
-17.05%
5.25
-20.22%
6.58
+182.57%
2.33
Stock Based Compensation
37.64
-27.25%
51.74
-21.54%
65.95
-21.11%
83.60
Asset Impairment Charge
2.38
-86.52%
17.67
-12.70%
20.25
—
Deferred Tax
0.00
-100.00%
0.44
0.00
—
Deferred Income Tax
0.00
-100.00%
0.44
0.00
—
Operating Gains Losses
—
1.69
-84.18%
10.67
-17.16%
12.88
Change In Working Capital
-10.88
+56.14%
-24.80
-16.39%
-21.31
-646.75%
3.90
Change In Prepaid Assets
3.24
+758.13%
-0.49
-145.30%
1.09
-56.85%
2.52
Change In Payables And Accrued Expense
-3.75
-112.52%
-1.76
+87.68%
-14.32
-316.49%
6.62
Change In Accrued Expense
-2.52
-99.68%
-1.26
+81.50%
-6.82
-490.11%
1.75
Change In Payable
-1.23
-144.73%
-0.50
+93.30%
-7.50
-254.11%
4.87
Change In Account Payable
-1.23
-144.73%
-0.50
+93.30%
-7.50
-254.11%
4.87
Change In Other Working Capital
-2.71
+86.97%
-20.77
-692333.33%
-0.00
+85.71%
-0.02
Change In Other Current Assets
-1.29
-130.15%
4.28
+394.09%
-1.46
+56.36%
-3.33
Change In Other Current Liabilities
-6.37
-5.29%
-6.05
+8.54%
-6.61
-251.38%
-1.88
Investing Cash Flow
95.56
+26.25%
75.69
-53.65%
163.29
+53.82%
106.16
Cash Flow From Continuing Investing Activities
95.56
+26.25%
75.69
-53.65%
163.29
+53.82%
106.16
Net PPE Purchase And Sale
-0.39
+44.38%
-0.69
+54.22%
-1.52
+70.80%
-5.19
Purchase Of PPE
-0.39
+44.38%
-0.69
+54.22%
-1.52
+70.80%
-5.19
Capital Expenditure
-0.39
+44.38%
-0.69
+54.22%
-1.52
+70.80%
-5.19
Net Investment Purchase And Sale
95.94
+25.61%
76.38
-53.65%
164.81
+48.01%
111.35
Purchase Of Investment
-138.26
+61.75%
-361.48
+17.59%
-438.63
-76.79%
-248.11
Sale Of Investment
234.20
-46.51%
437.86
-27.44%
603.43
+67.87%
359.46
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Financing Cash Flow
30.16
-74.15%
116.67
+21.92%
95.69
+3143.90%
2.95
Cash Flow From Continuing Financing Activities
30.16
-74.15%
116.67
+21.92%
95.69
+3143.90%
2.95
Net Common Stock Issuance
22.35
-80.05%
112.05
+22.98%
91.11
0.00
Proceeds From Stock Option Exercised
0.90
-61.88%
2.35
-48.77%
4.58
+55.36%
2.95
Net Other Financing Charges
6.91
+202.98%
2.28
—
—
Changes In Cash
-23.53
-196.46%
-7.94
-137.35%
21.25
+119.07%
-111.41
Beginning Cash Position
85.51
-8.49%
93.45
+29.44%
72.20
-60.68%
183.61
End Cash Position
61.98
-27.52%
85.51
-8.49%
93.45
+29.44%
72.20
Free Cash Flow
-149.63
+25.55%
-200.99
+15.99%
-239.25
-6.00%
-225.71
Amortization Of Securities
-4.22
+49.44%
-8.35
-22.60%
-6.81
-335.52%
2.89
Common Stock Issuance
22.35
-80.05%
112.05
+22.98%
91.11
0.00
Earnings Losses From Equity Investments
0.00
-100.00%
1.69
-84.18%
10.67
-17.16%
12.88
Issuance Of Capital Stock
22.35
-80.05%
112.05
+22.98%
91.11
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category